Pharmaceutical Information |
Drug Name |
Raltegravir |
Drug ID |
BADD_D01905 |
Description |
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. |
Indications and Usage |
For the treatment of HIV-1 infection in conjunction with other antiretrovirals. |
Marketing Status |
approved |
ATC Code |
J05AJ01 |
DrugBank ID |
DB06817
|
KEGG ID |
D06676
|
MeSH ID |
D000068898
|
PubChem ID |
54671008
|
TTD Drug ID |
D0I1FQ
|
NDC Product Code |
0006-0477; 0006-3603; 50090-1085; 65977-0049; 82982-055; 17381-749; 0006-0227; 53002-1686; 71205-777; 68071-2113; 0006-3080; 0006-0473 |
UNII |
22VKV8053U
|
Synonyms |
Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress |
|
Chemical Information |
Molecular Formula |
C20H21FN6O5 |
CAS Registry Number |
518048-05-0 |
SMILES |
CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|